Martingale Asset Management L P Boosts Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Martingale Asset Management L P raised its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,971 shares of the company’s stock after purchasing an additional 140 shares during the quarter. Martingale Asset Management L P owned 0.07% of Prestige Consumer Healthcare worth $2,666,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in PBH. Townsquare Capital LLC boosted its position in Prestige Consumer Healthcare by 8.8% in the 3rd quarter. Townsquare Capital LLC now owns 77,168 shares of the company’s stock valued at $5,564,000 after buying an additional 6,249 shares during the period. BNP Paribas Financial Markets grew its stake in Prestige Consumer Healthcare by 276.2% in the third quarter. BNP Paribas Financial Markets now owns 17,379 shares of the company’s stock worth $1,253,000 after purchasing an additional 12,759 shares in the last quarter. Horizon Kinetics Asset Management LLC increased its holdings in Prestige Consumer Healthcare by 4.8% during the 3rd quarter. Horizon Kinetics Asset Management LLC now owns 3,247 shares of the company’s stock worth $234,000 after purchasing an additional 150 shares during the period. Cerity Partners LLC lifted its holdings in shares of Prestige Consumer Healthcare by 103.9% in the 3rd quarter. Cerity Partners LLC now owns 6,347 shares of the company’s stock worth $458,000 after buying an additional 3,234 shares during the period. Finally, Citigroup Inc. increased its stake in shares of Prestige Consumer Healthcare by 66.6% during the third quarter. Citigroup Inc. now owns 76,772 shares of the company’s stock valued at $5,535,000 after buying an additional 30,677 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PBH has been the topic of a number of research reports. Jefferies Financial Group reissued a “hold” rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson reaffirmed a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $83.67.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total value of $743,166.00. Following the sale, the executive vice president now directly owns 18,365 shares of the company’s stock, valued at $1,505,930. This trade represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock worth $3,187,300 in the last three months. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $84.77 on Friday. Prestige Consumer Healthcare Inc. has a 12-month low of $56.61 and a 12-month high of $86.36. The firm’s fifty day simple moving average is $75.41 and its two-hundred day simple moving average is $71.16. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $4.19 billion, a P/E ratio of 20.63, a P/E/G ratio of 2.37 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.07 EPS. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.